Best Method of PRP preparation for knee joint infiltration for maximum benefit
"platelet-rich plasma"[MeSH Terms] AND "knee"[MeSH Terms] AND preparation
PRP preparation method knee joint injection maximum benefit leukocyte concentration centrifugation 2024 2025
"platelet-rich plasma" AND "knee osteoarthritis" AND preparation
https://asra.com/news-publications/asra-newsletter/newslette…
PMID: 36502442
PMID: 38525952
"leukocyte-poor" OR "leukocyte-rich" AND "platelet-rich plasma" AND "knee osteoarthritis"
PMID: 36173473
PMID: 41629990
PMID: 39394763
| Parameter | Recommendation |
|---|---|
| Volume | 20–60 mL whole blood (to yield 3–6 mL PRP) |
| Anticoagulant | Acid citrate dextrose (ACD) or sodium citrate 3.2% — prevents platelet activation during processing |
| Needle gauge | 19–21G — avoid smaller gauges that shear platelets |
| Avoid | Heparin (alters growth factor binding); EDTA (inhibits platelet activation needed post-injection) |
Critical platelet concentration threshold: ASRA 2025 analysis of 8 clinical trials found all 4 positive trials used PRP at ≥3× baseline platelet concentration; all 4 negative trials had only 1.2–1.7× baseline. Target ≥3× baseline (ideally ~1,000,000–1,500,000 platelets/µL).
| Evidence Source | Finding |
|---|---|
| Xu et al., 2026 — Network meta-analysis, 21 RCTs, 2,254 patients (PMID 41629990) | Both LP-PRP and LR-PRP superior to HA and placebo. LP-PRP P-score for function = 0.96 vs LR-PRP 0.82. No statistically significant direct difference. |
| Romandini et al., 2024 — Double-blind RCT, 132 patients, KL 1–3 (PMID 39394763) | No significant difference in IKDC, KOOS, WOMAC, VAS at 12 months between LR-PRP and LP-PRP. LR-PRP showed earlier improvement at 2 months; LP-PRP showed better ROM at 6 months. |
| Kim et al., 2023 — Meta-analysis, 21 RCTs (PMID 36173473) | Both LP-PRP and LR-PRP superior to HA at 6 and 12 months. LR-PRP had 3.3× higher odds of post-injection pain/swelling vs HA (OR 3.3, 95% CI 1.1–10.2). |
| ASRA 2025 review | Leukocyte concentration less predictive of success than platelet concentration. |
| Parameter | Evidence-Based Recommendation |
|---|---|
| Injection volume | 5–6 mL per knee (most positive trials used this range) |
| Number of injections | 3 injections at weekly intervals most commonly used in positive trials; single injection also effective |
| Injection guidance | Ultrasound guidance improves accuracy and reduces variability; preferred over landmark-based |
| Timing after preparation | Use within 8 hours of centrifugation to preserve leukocyte concentration and pH |
Blood draw: 20–60 mL in ACD anticoagulant (19–21G needle)
↓
Spin 1 (soft): ~130 × g × 10–15 min
↓
Transfer platelet-rich supernatant (avoid buffy coat for LP-PRP)
↓
Spin 2 (hard): ~300–400 × g × 10–15 min
↓
Discard upper PPP, resuspend platelet pellet in 5–6 mL plasma
↓
Verify: platelet count ≥3× baseline (ideally ~1,000,000–1,500,000/µL)
↓
Activate with CaCl₂ immediately before injection
↓
Inject under ultrasound guidance into knee joint
For spin 1 and 2 give RMP rate of centrifuge machine
RPM = 1000 × √(RCF ÷ (1.118 × r_cm))
| Spin | Target RCF | RPM (10 cm rotor) | Duration |
|---|---|---|---|
| Spin 1 (soft spin) | 100–160 × g | 950–1200 RPM | 10–15 min |
| Spin 2 (hard spin) | 250–400 × g | 1500–1900 RPM | 10–15 min |
| Protocol | Spin 1 | Spin 2 |
|---|---|---|
| Perez et al. (optimal single spin) | 100 × g → 950 RPM | — |
| Double-spin standard | 130 × g → 1080 RPM / 10 min | 340 × g → 1750 RPM / 10 min |
| Anitua / PRGF-Endoret system | 460 × g → 2100 RPM / 8 min (single spin, extracts layer just above RBC) | — |
| Harvest SmartPrep | ~200 × g → 1300 RPM | ~400 × g → 1900 RPM |
| Biomet GPS III | ~1500 RPM / 15 min (single spin) | — |
Practical standard for a generic bench centrifuge with 10 cm rotor:
- Spin 1: 1200 RPM × 10 min
- Spin 2: 1800 RPM × 10 min
RPM = 1000 × √(RCF ÷ (0.01118 × r_mm))
Also mention amount of anticoagulant and activator calcium chloride to be used
"platelet-rich plasma" AND "calcium chloride" AND activation AND concentration
PRP preparation anticoagulant ACD ratio blood calcium chloride activation concentration ratio protocol
https://www.frontiersin.org/journals/cell-and-developmental-…